Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products … Read more
Corline Biomedical AB (CLBIO) - Total Liabilities
Latest total liabilities as of September 2025: Skr5.09 Million SEK
Based on the latest financial reports, Corline Biomedical AB (CLBIO) has total liabilities worth Skr5.09 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Corline Biomedical AB - Total Liabilities Trend (2012–2024)
This chart illustrates how Corline Biomedical AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Corline Biomedical AB Competitors by Total Liabilities
The table below lists competitors of Corline Biomedical AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eyesvision Corp
KQ:031310
|
Korea | ₩85.51 Billion |
|
Secova Metals Corp
OTCQB:SEKZF
|
USA | $3.82 Million |
|
Nasus Pharma Ltd.
NYSE MKT:NSRX
|
USA | $3.93 Million |
|
Silverline Endustri ve Ticaret AS
IS:SILVR
|
Turkey | TL886.75 Million |
|
TRANSDIGM
BE:T7D
|
Germany | €31.87 Billion |
|
Konsortium Transnasional Bhd
KLSE:4847
|
Malaysia | RM191.01 Million |
|
Two Hands Corp
PINK:TWOH
|
USA | $3.34 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Corline Biomedical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.14 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corline Biomedical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corline Biomedical AB (2012–2024)
The table below shows the annual total liabilities of Corline Biomedical AB from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr7.85 Million | +15.60% |
| 2023-12-31 | Skr6.79 Million | -5.63% |
| 2022-12-31 | Skr7.19 Million | -23.69% |
| 2021-12-31 | Skr9.43 Million | +50.83% |
| 2020-12-31 | Skr6.25 Million | +40.99% |
| 2019-12-31 | Skr4.43 Million | -44.26% |
| 2018-12-31 | Skr7.95 Million | +44.57% |
| 2017-12-31 | Skr5.50 Million | +117.52% |
| 2016-12-31 | Skr2.53 Million | -32.46% |
| 2015-12-31 | Skr3.74 Million | -66.83% |
| 2014-12-31 | Skr11.29 Million | +95.96% |
| 2013-12-31 | Skr5.76 Million | -48.05% |
| 2012-12-31 | Skr11.09 Million | -- |